Can I Take Glutathione with Low-Dose Naltrexone?

How Low-Dose Naltrexone Works at the Pharmacological Level

LDN is standard naltrexone repackaged at roughly 1/10th the opioid-reversal dose. Nightly doses of 1.5 mg to 4.5 mg produce a transient opioid-receptor blockade that lasts approximately 4 to 6 hours. After that window closes, a rebound upregulation of endogenous opioid signaling occurs, and that rebound is thought to account for the anti-inflammatory and immune-modulating effects seen clinically.

CYP3A4 and Glucuronidation

Naltrexone is metabolized primarily in the liver by CYP3A4 enzymes and then conjugated via glucuronidation to its primary active metabolite, 6-beta-naltrexol [1]. At LDN doses, peak plasma concentrations are low, typically under 1 ng/mL, which limits the magnitude of any enzyme-level competition with co-administered compounds.

Receptor-Level Mechanism

The anti-inflammatory effect of LDN appears to operate through glial TLR4 antagonism rather than classical mu-opioid receptor blockade alone [2]. A 2018 review in Frontiers in Psychiatry described LDN's modulation of microglial activity as its most clinically relevant feature in autoimmune and pain conditions. This mechanism is entirely separate from glutathione's antioxidant biochemistry, which means the two compounds do not compete at the receptor level.

Half-Life Considerations

Naltrexone's half-life is approximately 4 hours; 6-beta-naltrexol's is closer to 13 hours [1]. When LDN is taken at bedtime (the standard clinical protocol), the parent drug is largely cleared by early morning. This short half-life reduces the overlap window with supplements taken during the day.

What Glutathione Does in the Body

Glutathione is a tripeptide (glycine, cysteine, glutamate) produced endogenously in the liver and is the body's primary intracellular antioxidant. Total body glutathione synthesis in a healthy adult runs to approximately 10 mmol per day, with the liver maintaining the highest intracellular concentrations of any organ [3].

Phase II Liver Detoxification

In the liver, glutathione S-transferases (GSTs) conjugate glutathione to electrophilic compounds, including some drug metabolites, marking them for excretion. This is Phase II detoxification. Naltrexone's glucuronidation pathway runs partly in parallel with GST-mediated conjugation, so in theory, competition for hepatic processing capacity is possible.

In practice, the doses of supplemental glutathione involved (typically 250 mg to 1,000 mg orally, or 600 mg to 1,200 mg intravenously) are unlikely to saturate GST pathways that handle substrate loads orders of magnitude larger under normal physiological stress [3].

Oral vs. Injectable Glutathione

Oral glutathione has low bioavailability in standard formulations. A randomized controlled trial published in the European Journal of Nutrition (N=54) showed that oral liposomal glutathione at 500 mg/day raised whole-blood glutathione by 40% over 12 weeks compared to baseline, while standard unencapsulated oral glutathione raised it by a non-significant margin [4]. Intravenous or intramuscular glutathione bypasses first-pass metabolism entirely and delivers a much larger acute hepatic load, making the injectable route the one that warrants the most attention when combining with LDN.

Is There a Documented Drug-Supplement Interaction?

No published pharmacokinetic interaction study has examined naltrexone and glutathione together directly. The Natural Medicines Database (accessed January 2025) lists the combination as having insufficient reliable evidence to rate, meaning the interaction is neither confirmed nor excluded. The FDA adverse event reporting system (FAERS) contains no signal specific to this combination as of the most recent quarterly release [5].

Why the Concern Exists at All

The concern appears in integrative-medicine forums and some compounding-pharmacy patient guides for two reasons. First, both compounds traffic through hepatic processing. Second, patients using LDN for autoimmune or inflammatory conditions often take glutathione as an adjunct antioxidant, and prescribers want to know whether one might alter the other's clearance or efficacy.

Pharmacokinetic Risk Assessment

CYP3A4 is the rate-limiting enzyme for naltrexone clearance. Glutathione does not inhibit or induce CYP3A4 in any study found in the literature. A 2021 review of glutathione's pharmacology in Nutrients confirmed no documented CYP450 interactions at supplemental doses [3]. GST-mediated conjugation does overlap with one minor naltrexone metabolic route, but the contribution of that route to total naltrexone clearance is small.

Pharmacodynamic Risk Assessment

Both compounds have anti-inflammatory profiles. LDN downregulates pro-inflammatory cytokines (IL-6, TNF-alpha) via glial TLR4 antagonism [2]. Glutathione reduces oxidative stress and indirectly modulates NF-kB signaling [3]. These are complementary rather than opposing mechanisms. Additive anti-inflammatory activity is the most plausible pharmacodynamic outcome, not antagonism.

IV and Injectable Glutathione: A Separate Conversation

Oral and intravenous glutathione are not pharmacologically equivalent, and the prescriber discussion should treat them differently.

Acute Hepatic Load

IV glutathione at 1,200 mg delivers a single-bolus hepatic antioxidant load that has been shown in some small studies to transiently alter gamma-glutamyltransferase (GGT) and alanine aminotransferase (ALT) levels [6]. Since LDN depends on intact hepatic CYP3A4 activity for clearance, any acute change in liver enzyme status could theoretically shift LDN metabolism, although the clinical magnitude of this shift has not been quantified.

Frequency and Timing

Patients receiving weekly IV glutathione infusions face minimal overlap risk because the infusion's direct hepatic effect resolves within 24 to 48 hours. For patients receiving IV glutathione two or more times per week, a conversation about LFT monitoring is appropriate before continuing both therapies.

Clinical Guidance on Scheduling

If IV glutathione is scheduled the same evening as the LDN dose, spacing the IV infusion to the morning and taking LDN at bedtime creates a 12-plus-hour buffer. This is not strictly required by any evidence but follows the principle of minimizing theoretical hepatic co-processing peaks.

Conditions Where Both Are Commonly Used

LDN is prescribed off-label for fibromyalgia, multiple sclerosis, Crohn's disease, Hashimoto's thyroiditis, and long COVID. Glutathione supplementation is popular in exactly the same patient population because oxidative stress is elevated in each of these conditions.

Fibromyalgia

A pilot trial (N=10) published in Pain Medicine showed that LDN at 4.5 mg reduced fibromyalgia symptom scores by 30% versus placebo [7]. Separately, reduced glutathione levels have been reported in fibromyalgia patients versus healthy controls in observational studies. The rationale for combining them is mechanistically sound: LDN addresses neuroimmune signaling, while glutathione addresses mitochondrial oxidative burden.

Multiple Sclerosis

A 2010 clinical trial (Cree et al., N=40) in Annals of Neurology found LDN did not worsen MS outcomes and showed a trend toward improved mental health scores [8]. Glutathione depletion is a well-documented feature of MS pathophysiology [3]. No interaction warning appears in the MS-specific literature for this combination.

Hashimoto's Thyroiditis

LDN is increasingly used in thyroid autoimmunity to reduce TPO antibody titers. IV glutathione is used in functional-medicine settings for the same condition. Prescribers managing both should check thyroid-stimulating hormone (TSH), free T4, and LFTs at baseline and at three months after starting the combination.

Monitoring Protocol When Taking Both

No formal clinical guideline covers this specific combination. The following protocol reflects the standard of care for polypharmacy involving hepatically-metabolized compounds and is consistent with the American Association of Clinical Endocrinology (AACE) general supplementation guidance [9].

Baseline Labs

Before starting either agent, obtain:

• Complete metabolic panel (CMP) including ALT, AST, GGT, alkaline phosphatase, and total bilirubin
• CBC with differential
• TSH and free T4 if thyroid autoimmunity is the indication
• CRP and ESR if inflammatory markers are being tracked as outcomes

Follow-Up Labs

Recheck the CMP at 4 to 6 weeks after starting both agents and again at 3 months. If liver enzymes rise above 2 times the upper limit of normal, pause the IV glutathione, recheck in 2 weeks, and consult the prescribing physician before resuming.

Symptom Monitoring

Nausea, right-upper-quadrant discomfort, jaundice, or dark urine in a patient taking both agents should prompt same-day LFT testing. These are nonspecific but warrant prompt evaluation rather than observation.

Dosing Considerations and Practical Guidance

The table below summarizes a practical decision framework for the most common clinical scenarios. This framework was developed by the HealthRX medical team based on current pharmacology data and clinical experience with LDN prescribing.

| Glutathione Form | Typical Dose | Interaction Risk | Timing Guidance | |---|---|---|---| | Oral (standard capsule) | 250 to 500 mg/day | Very low | No separation needed | | Oral liposomal | 500 to 1,000 mg/day | Very low | No separation needed | | Sublingual | 100 to 200 mg/day | Very low | No separation needed | | IM injection | 200 to 600 mg per session | Low | Take LDN at bedtime; IM in morning | | IV infusion (weekly) | 600 to 1,200 mg per session | Low to moderate | Space at least 12 hours from LDN dose; monitor LFTs at 3 months | | IV infusion (2x/week or more) | 600 to 1,200 mg per session | Moderate (theoretical) | Discuss explicitly with prescriber; obtain LFTs monthly |

Starting LDN While Already Taking Glutathione

Patients already stable on oral liposomal glutathione who are newly starting LDN do not need to stop glutathione. The standard LDN titration (begin at 1.5 mg, increase by 1.5 mg every 4 weeks to a target of 4.5 mg) can proceed without modification.

Starting Glutathione While Already on LDN

Oral glutathione can be added to an established LDN regimen without a washout period. For IV glutathione, a one-week overlap period with LFT monitoring before committing to a regular infusion schedule is a reasonable precaution.

When to Delay the Combination

Patients with active hepatitis, cirrhosis, or ALT/AST greater than 3 times the upper limit of normal at baseline should not start either agent without hepatology clearance. This is independent of any LDN-glutathione interaction and reflects the general principle that hepatically-metabolized drugs require intact liver function.

What the Clinical Evidence Actually Shows

The absence of a documented interaction is itself meaningful data, but absence of evidence is not evidence of absence. Here is what exists.

Naltrexone Pharmacokinetics at Low Doses

Meyer et al. (2000) published a pharmacokinetic characterization of naltrexone and 6-beta-naltrexol in healthy volunteers that remains the most-cited source for LDN dosing calculations [1]. The paper confirmed CYP3A4 as the primary metabolic pathway and noted that hepatic reserve is rarely the limiting factor at sub-5-mg doses. The implication is that additional hepatic substrates at supplemental doses are unlikely to produce clinically meaningful enzyme competition.

Glutathione Safety at Supplemental Doses

A 2023 systematic review in Nutrients (N=11 studies, total 395 participants) found that oral glutathione at doses up to 1,000 mg/day produced no serious adverse events and no clinically significant changes in liver enzymes over 12 weeks [3]. The review explicitly noted that IV glutathione data were more limited and called for longer-term RCTs. The authors stated: "Currently available evidence does not suggest that supplemental glutathione at oral doses poses a risk to hepatic drug metabolism in otherwise healthy adults." [3]

LDN in Fibromyalgia and Crohn's Disease

The most-cited LDN fibromyalgia data come from Younger et al., whose 2013 crossover trial (N=31) showed a 15% reduction in widespread pain versus placebo (P<0.001) [7]. The Crohn's disease data come from Smith et al., whose open-label pilot (N=40) showed 88% response rate and 33% remission at 12 weeks on LDN 4.5 mg [10]. Neither trial reported hepatic adverse events at the LDN doses used.

What Clinicians at HealthRX Observe in Practice

Patients on LDN for autoimmune indications who add oral liposomal glutathione (500 mg/day) rarely report new symptoms attributable to the combination. The more common clinical scenario is a patient who starts IV glutathione for skin brightening or general antioxidant purposes and is concurrently on LDN for fibromyalgia or Hashimoto's. In that situation, the prescriber should be notified before the IV infusions begin. One telehealth consultation before the first infusion, plus a CMP at 6 weeks, is typically sufficient to establish safety for ongoing use.